All Posts

This RCT 1  enrolled 437 secondary care patients aged ≥65 years (mean 75) with CHA₂DS₂-VASc scores ≥2 in men and ≥3 in women. Participants were assigned to 6-month (180-day) monitoring, using an Apple smartwatch with photoplethysmography and single-lead ECG functions, or to standard care.  Over 6 months, atrial fibrillation (AF) was detected in 21 patients (9.6%) in the intervention group versus 5 (2.3%) in controls. Several asymptomatic AF episodes were identified only in th

Nurse Practitioner Permanent full-time 0.9-1.0 FTE | Salary $142,470-$157,252 depending on experience The Gardens, Manurewa location, with free parking on site Onsite café with discounted coffee, health insurance, boutique 2 nd edition store and more… At Tōtara Hospice, you’re not just a nurse — you’re a purpose-driven clinician making a real impact every day.   Imagine starting your morning surrounded by native trees, peaceful gardens, and a calm oasis far from the city rus

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 27 March 2026. It includes information on:  New updates Resolved Supply Issues Supply issue: Dexamfetamine 5 mg tablets There is a supply issue affecting the Noumed brand of dexamfetamine 5 mg tablets. The supplier has advised that stock will be unavailable from April to June 2026. From 1 April, the Aspen brand of dexamfetamine 5 mg tablets will be

Kia ora, Please follow this  link  to our website for the March 2026 Tender Notification. Ngā mihi, Stefanie Moir | Tender Analyst Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington | P: 0800 660 050 |  www.pharmac.govt.nz

Triple0 is currently working with a modern, newly established practice in Christchurch that's continuing to grow, and they're looking for a Nurse Practitioner to join their supportive, forward-thinking team.   While a permanent role is preferred, there's also flexibility with a 6–12 month option—ideal if you're considering relocating or keen to experience a new environment before committing longer term.   ✨ What's on offer: Competitive rates Positive, collaborative team cultu

Enhance your Dermatology Expertise: Join Our Online Session on Saturday, 16 May. Skin conditions are among the most frequent presentations in primary care. This 4-hour webinar brings together top New Zealand dermatology specialists to help you navigate these complexities with confidence. What to expect: Expert-led, primary care–focused updates on recognising and managing common dermatology presentations seen in everyday practice. Practical guidance on diagnosing and treating

Conflict in the Middle East Suppliers are working closely with Pharmac to reduce any disruption to people in New Zealand. Where issues arise, we will communicate them on our website and through this email. Conflict in the Middle East: Impact on the supply chain New medicine supply notices Ensure: Pack size change  Ensure powders are changing from 850 g to 800 g. The price remains the same. New Pharmacodes are listed from 1 April. New packs will start arriving during June 2026

We are writing to inform you of - Supply issue: Proctosedyl suppository. New alternative listed: Scheriproct suppository. Key messages: The supplier (AFT) has informed Pharmac that due to a delayed shipment that Proctosedyl suppositories are out of stock. Scheriproct suppositories have been listed (funded) on the Pharmaceutical Schedule. Scheriproct suppositories will be available in New Zealand by early April. Ultraproct suppositories have been out of stock for a long period

Kia ora This link  will take you to the proposal to award Principal Supply Status for permanent coronary drug-eluting stents to Medtronic New Zealand Limited. A list of products included in the proposal is attached . Pharmac welcomes feedback on this proposal. To provide feedback, please submit it in writing by 4pm Tuesday 28 April 2026  to Sam.Edlund@Pharmac.govt.nz   Ngā mihi, Sam Edlund | Procurement Manager _______________________________________________________________

Our latest webinars and podcasts for you:  Whole of life protection: A focus on adult vaccination WEBINAR 14 April: Nikki Turner on the importance of adult immunisation as part of comprehensive preventive care in primary practice.  Register here   Redefining insomnia management WEBINAR 21 April: David Cunnington, a specialist sleep physician, will review contemporary insomnia management, including CBT-I, and discuss the role of medications, including lemborexant, a newer agen

Please see attached latest Research Review

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 20 March 2026. It includes information on:  New updates Resolved Supply Issues Enoxaparin inj 100 mg per ml (1 ml syringe) (Clexane) For Primary Response in Medical Emergencies PRIME services Only the Enoxaparin inj 100 mg per ml (1 ml syringe) is funded on a Practitioner Supply Order (PSO) with an endorsement limiting funding to PRIME indications.

Leadership opportunity for an experienced Registered Nurse in mental health $105,812 + complexity allowance + 5 weeks AL + 2 paid well-being days HealthNow Payment Card - $250 per year + Increased KiwiSaver contribution    Lead our Nelson-based respite mental health service in a permanent full-time, Monday–Friday leadership role. What we offer | Ngā āhuatanga kei a mātou $105,812 + complexity allowance Increased KiwiSaver contribution 5th week of annual leave (after 12 months

Acarbose (Accarb) 50 mg and 100 mg tablets  Delays to shipments means there is limited stock available of the acarbose 50 mg (Pharmacode: 2402408) and 100 mg (Pharmacode: 2402416) tablets. Next shipment is expected by the end of the month. Dexamfetamine (Noumed) 5 mg tab (Pharmacode: 2647516) Stock levels are low at the supplier. An alternative is listed from 1 April 2026. It is Medsafe registered but contains gluten. Epoetin alfa (Binocrit) inj 40,000 iu in 1 ml  (Pharmacod

About the Role Join us in making a difference in the lives of older people through expert, compassionate care. Equinox Health Ltd is seeking an experienced and motivated Nurse Practitioner to join our team providing care within residential aged care settings. This is a part-time position (approximately 12 hours per week), offering flexibility and the opportunity to work autonomously while delivering high-quality, patient-centred care to older adults. You will be working along

We’re seeking NPs for contract roles across NZ to provide weekly rounds to Aged Residential Care (ARC) facilities, delivering high-quality care to older patients with complex needs.   We currently have opportunities across Northland, Waikato, Bay of Plenty, Taranaki, Manawatu, Hawkes Bay, Wairarapa, Greater Wellington, Blenheim and Wanaka.   You will work closely with onsite nurses and care teams to: Provide excellent clinical care to ARC residents (rest home level care and a

Pharmac have now gone live with public consultation feedback on the Exceptional Circumstances Framework (the Framework) including the Named Patient Pharmaceutical Assessment (NPPA) . We would appreciate your help in sharing this consultation with your networks, particularly anyone who may have experience of, or interest in, the Exceptional Circumstances Framework. Patients, whānau, clinicians, and others have told us that the current Framework is no longer fit for purpose and

Issue 338 - 19 March 2026 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here . You can also access other recent issues of the digest here. If you have any queries, please email us at  library@health.govt.nz . Article Access For articles that aren't

The benefit of beta‑blockers after myocardial infarction in patients with preserved left ventricular ejection fraction (LVEF ≥50%) is uncertain. This individual‑patient meta‑analysis combined five open‑label randomised trials, including 17,801 patients without other indications for beta-blockers 1 .  Participants were assigned to beta‑blocker therapy or no therapy, and the primary outcome was a composite of all‑cause death, myocardial infarction, or heart failure. After a med

We are getting in touch to let you know that Pharmac is seeking feedback on the Exceptional Circumstances Framework (the Framework), and we’d like to hear from you. The Framework outlines how Pharmac considers funding requests for people with exceptional clinical circumstances when those circumstances fall outside the Pharmaceutical Schedule funding process. Patients, whānau, clinicians, and others have told us that the current Framework is no longer fit for purpose and can